Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid, Carrie Strand, Jack Fiskum, Michael Menefee, Grace Lin, L. Austin Doyle, Percy Ivy, Charles Erlichman, Alex Adjei, Paul Haluska, Brian A. Costello

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences